Recurrent gliomas: Comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy

• Published in: Cancer biology & therapy 2012-08, Vol.13 (10), p.840-847
• Main Authors: Hu, Xiaokun, Qiu, Huijuan, Zhang, Liang, Zhang, Weidong, Ma, Yongqiang, Qiao, Zhizheng, Chen, Dong, Han, Jianjun, Duan, Guangfeng, Zhang, Fujun
• Format: Article
• Language: English
• Subjects: Adult; Aged; Binding; Biology; Bioscience; brachytherapy; Brachytherapy - adverse effects; Brain - pathology; Brain Neoplasms - mortality; Brain Neoplasms - radiotherapy; Brain Neoplasms - therapy; Calcium; Cancer; Cell; Chemoradiotherapy - adverse effects; Combined Modality Therapy; computed tomography (CT)-guided implantation; Cycle; Female; glioma; Glioma - mortality; Glioma - radiotherapy; Glioma - therapy; Humans; Iodine Radioisotopes - therapeutic use; Landes; Male; Middle Aged; Neoplasm Grading; Organogenesis; Proteins; radiochemotherapy; Tomography, X-Ray Computed; Treatment Outcome
• ISSN: 1538-4047; 1555-8576
• DOI: 10.4161/cbt.20834

Background: Primary brain tumors have always been associated with high morbidity and mortality. Glioma is the most common type of malignant brain tumors,with a high probability of recurrence after surgical excision and with poor prognosis.The purpose of this study was to compare the therapeutic efficacy of computed tomography (CT)-guided interstitial 125 I seed implantation with traditional radiochemotherapy for treatment of recurrent gliomas. Results: The response rate at 1, 3, 6 and 12 months after 125 I seed implantation was 68.6, 74.3, 77.1 and 62.8% respectively, which was significantly higher than the group treated with the conventional chemoradiation protocol (p < 0.05). Patients exposed to 125 I seed implantation had a median survival of 29.0 months, whereas the median survival of those treated with traditional radiochemotherapy was 19.0 months. The difference observed between the two groups was significant. There were no severe complications or mortality associated with either treatment, except for one case of intracerebral hemorrhage around the tumor area in the 125 I seed implants group. Methods: From November 2002 to May 2010, 73 consecutive patients with recurrent gliomas were treated with CT-guided 125 I seed implantation (35 cases) or traditional radiochemotherapy (38 cases). Patients were followed up after treatment and the therapeutic effect was evaluated by comparing the response and survival rates of the two groups. In particular, patients treated with 125 I seed implantation were monitored for adverse side effects. Conclusions: CT-guided 125 I seed implantation is safe and well-tolerated and more importantly, shows superior efficacy compared with conventional radiochemotherapy. This suggests that CT-guided 125 I seed implantation could be an alternative approach for recurrent gliomas.